Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

Dual IO 2021 Year in Review

Dual IO 2021 Year in Review

Phase 2 Study of Nivolumab plus Ipilimumab in Metastatic Uveal Melanoma

Dual IO 2021 Year in Review

Phase 2 Trial of Nivolumab plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: Spanish Multidisciplinary Melanoma Group (GEM-1402)

Dual IO 2021 Year in Review

Benefits of Dual I-O Therapy in Metastatic Uveal Melanoma

Sanjiv S. Agarwala, MD

Dual IO 2021 Year in Review

Relatlimab plus Nivolumab versus Nivolumab Alone in First-Line Advanced Melanoma: Primary Results from RELATIVITY-047

Dual IO 2021 Year in Review

Nivolumab plus Ipilimumab as First-Line Therapy in Patients with Advanced Melanoma: 6.5-Year Update from CheckMate-067

Dual IO 2021 Year in Review

Nivolumab plus Relatlimab in the Neoadjuvant and Adjuvant Settings for Patients with Resectable Clinical Stage III Melanoma

Dual IO 2021 Year in Review

Dual Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma

Sanjiv S. Agarwala, MD

Dual IO 2021 Year in Review

Phase 2 Study of the Anti-TIGIT Antibody Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab as First-Line Treatment in Patients with PD-L1–Selected NSCLC: CITYSCAPE

Dual IO 2021 Year in Review

COAST: An Open-Label, Randomized, Phase 2 Platform Study of Durvalumab Alone or in Combination with Novel Agents in Patients with Locally Advanced, Unresectable, Stage III NSCLC

Dual IO 2021 Year in Review

First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma: 3-Year Update from CheckMate-743

Page 1 of 2
Results 1 - 10 of 15